Startups
AGE1 is an accelerator for longevity companies.
Longevity is at an inflection point: due to scientific advances over the last 30 years, we are beginning to change how we interact with chronological age, living a longer number of healthy years than ever before. Here and now, we embark on this journey.
Age1 is a 4-month program based in SF which offers both capital and help to launch founder-driven biotechnology companies. We are selecting a small group of innovative scientists and technologists who are working to extend human healthspan to bring to San Francisco. We invest in them and their ideas, connect them with the best mentors and advisors, and help them reach critical inflection points faster.
AGE1 is backed and advised by The Longevity Fund, Laura Deming, Felicis Ventures, Marc Andreessen, Elad Gil, and Founders Fund.
Longevity is at an inflection point: due to scientific advances over the last 30 years, we are beginning to change how we interact with chronological age, living a longer number of healthy years than ever before. Here and now, we embark on this journey.
Age1 is a 4-month program based in SF which offers both capital and help to launch founder-driven biotechnology companies. We are selecting a small group of innovative scientists and technologists who are working to extend human healthspan to bring to San Francisco. We invest in them and their ideas, connect them with the best mentors and advisors, and help them reach critical inflection points faster.
AGE1 is backed and advised by The Longevity Fund, Laura Deming, Felicis Ventures, Marc Andreessen, Elad Gil, and Founders Fund.
Overview
Location
United States, California, San Francisco
Mentions in press and media 11
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Feb 17, 2026 | Irish Biotech Aerska Secures $39M for Brain Shuttle RNA Medicines | Aerska, an Irish biotech firm, secured a $39 million Series A funding round. This significant investment will propel its proprietary brain shuttle technology. The platform targets challenging neurological diseases. It delivers RNA medicines... |
| Feb 12, 2026 | Loyal: $100 Million Series C Raised To Advance First Canine Longevity Drug | Loyal, a San Francisco–based clinical-stage animal health company developing lifespan extension drugs for dogs, has raised $100 million in Series C funding to support the advancement of its lead program, LOY-002, and move closer to market r... |
| Feb 12, 2026 | Aerska: $39 Million Series A Raised For Advancing Brain Shuttle RNA Medicines | Aerska, a biotechnology company developing brain shuttle technology to deliver RNA medicines to the central nervous system, has closed a $39 million Series A financing led by EQT Dementia Fund and age1, with participation from Iaso Ventures... |
| Feb 11, 2026 | Loyal Raises $100M in Series C Funding | Loyal, a San Francisco, CA-based clinical-stage animal health company, raised $100M in Series C funding. The round was led by age1 with participation from Baillie Gifford alongside existing investors. The raise brought the total amount to o... |
| Oct 1, 2025 | Irish biotech Aerska raises $21m to tackle neurological diseases | Irish biotech start-up Aerska has raised $21m (€19.5m) in seed funding to advance new genetic medicines aimed at treating and preventing neurological diseases such as Alzheimer’s and Parkinson’s. The company, founded by Irish entrepreneur J... |
| Sep 28, 2023 | age1 Closes $35 Million To Invest In Longevity Biotech Companies | age1 – a VC firm catalyzing the next generation of founder-led longevity biotech companies – recently launched to build a community of visionaries advancing new therapeutics, tools, and technologies targeting aging and age-related disease. ... |
| Sep 19, 2023 | age1 Launches to Back Longevity Biotech Companies | age1, a San Francisco, CA-based venture capital firm investing in the next generation of founder-led longevity biotech companies, officially launched. The firm, which held an initial closing for $35m, will invest in entrepreneurs advancing ... |
| Oct 15, 2018 | 'To them it was a science fiction story': A VC who's been investing in anti-aging research for 7 years explains why investors are starting to pour hundreds of millions into a field they had previously snubbed | YouTube/Hello Tomorrow Longevity Fund's Laura Deming. Advertisement When Laura Deming launched the Longevity Fund seven years ago, there weren't many investments going into experimental treatments aimed at helping us live healthie... |
| Sep 15, 2018 | 40 AND UNDER: The Silicon Valley biotech stars who are backing startups aiming to cure disease, prolong life, and fix the food system | This story is available exclusively to Insider subscribers. Become an Insider and start reading now. Putting millions of dollars into bold new technologies can be a delicate business when lives hang in the balance. But every day some of the... |
Show more
Reviews 0
FAQ about AGE1
What has the press written about AGE1?
Parsers VC has collected 11 articles mentioning AGE1, among them “Irish Biotech Aerska Secures $39M for Brain Shuttle RNA Medicines” (Feb 17, 2026) and “Loyal: $100 Million Series C Raised To Advance First Canine Longevity Drug” (Feb 12, 2026).
Is AGE1 still active?
Yes, AGE1 is active; its latest activity on Parsers VC dates from Feb 12, 2026.